N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...